Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression

Abstract

The present invention relates to in vitro methods of enriching populations of human pluripotent stem cells that are induced to differentiate to cardiomyocyte progenitor cells and cardiomyocyte cells. The cell populations can be enriched by isolating cells that express SIRPA. The invention also related to in vitro-enriched populations of cardiomyocyte cells and cardiomyocyte progenitor cells obtained from populations of pluripotent stem.

1 - 30 . (canceled) 
     
     
         31 . A composition comprising: a cell population comprising one or more of human cardiomyocytes and human cardiomyocyte progenitor cells; and a signal-regulatory protein alpha (SIRPA)-specific binding member. 
     
     
         32 . The composition of  claim 31 , wherein the cell population is derived from human pluripotent stem cells. 
     
     
         33 . The composition of  claim 32 , wherein the human pluripotent stem cells are selected from embryonic stem cells (hESCs) or human induced pluripotent stem cells (iPSCs). 
     
     
         34 . The composition of  claim 31 , wherein the SIRPA-specific binding member is selected from the group consisting of an anti-SIRPA antibody, an anti-SIRPA antibody fragment, and an anti-SIRPA antibody-like molecule. 
     
     
         35 . The composition of  claim 31 , wherein the cell population comprises at least 60% cardiomyocyte cells, cardiomyocyte progenitor cells, or both. 
     
     
         36 . The composition of  claim 35 , wherein the cell population comprises at least 90% cardiomyocyte cells, cardiomyocyte progenitor cells, or both. 
     
     
         37 . The composition of  claim 36 , wherein the cell population comprises at least 98% cardiomyocyte cells, cardiomyocyte progenitor cells, or both. 
     
     
         38 . The composition of  claim 31 , wherein the cell population is substantially devoid of cells expressing at least one of the following cell surface markers: CD90, CD31, CD140B and CD49A.